Certa is advancing the development of asengeprast in fibrotic diseases, with a focus on:
Future clinical studies are being designed to further evaluate efficacy and safety in these indications, including planned Phase 2b development programmes.
Disclaimer
Asengeprast (FT011) is an investigational therapy that has not been approved by regulatory authorities for commercial use.
